ASH Annual Meeting 2022
Advertisement
Patients who recover from grade 3-4 acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell ...
Researchers, led by Mark A. Schroeder, MD, conducted a single-arm, open-label phase 1 trial to evaluate the safety of ...
Haploidentical blood and marrow transplantation (BMT) has significantly increased the number of eligible hematopoietic ...
At the 64th ASH Annual Meeting and Exposition, researchers presented early findings from the dose-finding portion of ...
Chronic lymphocytic leukemia (CLL), a cancer of the blood and bone marrow that progresses over time, is one of the most ...
“Patients with chronic lymphocytic leukemia [CLL] have a higher risk of developing second primary malignancies ...
Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that progresses over time. The number of ...
In patients with chronic lymphocytic leukemia (CLL), targeted therapies significantly improve clinical outcomes and ...
A research paper presented by Andrea Visentin, MD, PhD, of the University of Padova in Italy, and colleagues at the 64th ...
According to Harinder Gill, MD, MBBS, FRCP, FRCPath, there is no optimal treatment strategy established for patients ...
In the phase 2 MANIFEST trial, John Mascarenhas, MD, and colleagues evaluated pelabresib, an oral bromodomain and ...
Studies have shown the JAK2 V617F somatic driver mutation is associated with disease progression in patients with ...
Researchers from the Division of Hematology at Mayo Clinic, led by Naseema Gangat, MBBS, sought to identify predictors ...
In a presentation at the 64th ASH Annual Meeting and Exposition, Franco Locatelli, MD, presented the first evidence ...
Previously, Katiri Snyder and colleagues determined that the enzyme protein arginine methyltransferase 5 (PRMT5) was ...
In a presentation at the 64th ASH Annual Meeting and Exposition, researchers presented findings from a pilot study on ...
Studies suggest that between 35% and 60% of patients with acute graft-versus-host disease (aGVHD) become resistant to ...
In a recent study, researchers from the Hope National Medical Center in Duarte, California, evaluated the safety and ...
Recently, the novel Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, belumosudil, was approved ...
In a phase 2 trial, presented at the 64th ASH Annual Meeting and Exposition, researchers compared itacitinib monotherapy ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.